Cognition After Lowering LDL-Cholesterol With Evolocumab

• Published in: Journal of the American College of Cardiology Vol. 75; no. 18; pp. 2283 - 2293
• Main Authors: Gencer, Baris, Mach, François, Guo, Jianping, Im, KyungAh, Ruzza, Andrea, Wang, Huei, Kurtz, Christopher E., Pedersen, Terje Rolf, Keech, Anthony C., Ott, Brian R., Sabatine, Marc S., Giugliano, Robert P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 12.05.2020
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - adverse effects; Atherosclerosis - blood; Atherosclerosis - drug therapy; Atherosclerosis - psychology; Cardiovascular; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - psychology; cholesterol; Cholesterol, LDL - antagonists & inhibitors; Cholesterol, LDL - blood; cognition; Cognition - drug effects; Cognition - physiology; Cognitive Dysfunction - blood; Cognitive Dysfunction - chemically induced; Cognitive Dysfunction - psychology; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; lipid-lowering therapies; Male; Middle Aged; PCSK9 inhibitor; safety; statin; PCSK9 inhibitor; CV; cognition; statin; LDL-C; safety; CI; ECog; CANTAB; cholesterol; PCSK9; lipid-lowering therapies; low-density lipoprotein cholesterol; cardiovascular; Cambridge Neuropsychological Test Automated Battery; Everyday Cognition; proprotein convertase subtilisin kexin 9; confidence interval
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2020.03.039

The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background statin did not affect cognitive performance in a subset of 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcome...